Kangpu Biopharmaceuticals Initiates Phase Ib/IIa Clinical Trial of KPG-818 in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE) is a complex, heterogeneous, inflammatory, chronic auto-immune disease in which the body's immune system attacks its own tissues, leading to widespread damage in various organs, including the kidneys, lungs, heart, ...

from Google Alert - Business https://ift.tt/3lDIWyw
Systemic Lupus Erythematosus (SLE) is a complex, heterogeneous, inflammatory, chronic auto-immune disease in which the body's immune system attacks its own tissues, leading to widespread damage in various organs, including the kidneys, lungs, heart, ... https://ift.tt/eA8V8J

Comments

Popular posts from this blog

Jobless Rate Drops

Electrolytic Fixed Power Capacitors Market Competitive intelligence & regional outlook 2020

USU project among finalists for $3 million solar energy tech prize